Calidi Biotherapeutics Inc. (CLDI)
CLDI trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1855485/000149315224010158/0001493152-24-010158-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CLDI on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Not reported by the screener |
| IPO year | 2021 |
| SEC CIK | 0001855485 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $45K |
| Net income | -$25.4M |
| Operating income | -$23.1M |
| Net margin | -56504.4% |
| Operating margin | -51395.6% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $590K |
| Total assets | $2.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 49.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $4.3M cash; operating cash flow -$4.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 3,449,184 (2026-11-11); 7,167,721 a year earlier; 35,436,381 three years earlier. 1y figure adjusted for splits (1-for-16 overall); 3y figure adjusted for splits (1-for-1920 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 3; latest 1-for-16 on 2026-07-31 | Source 2026-07-31 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-09-17 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-09-25 |
| Auditor | CBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.2M | -$4.4M | $4.3M | $600K | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$4.1M | -$4.1M | $6.8M | $600K | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$4.1M | -$5.0M | $5.8M | $600K | Needs four quarters | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | Not filed | -$5.1M | -$4.2M | $10.6M | $600K | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$5.7M | -$4.9M | $5.4M | $600K | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$5.0M | -$7.1M | $10.8M | $600K | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$4.1M | -$5.4M | $9.6M | $600K | Needs four quarters | 10-K 2026-03-27 |
| Q3 2024 2024-09-30 | Not filed | -$5.1M | -$4.9M | $1.9M | $2.4M | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-17 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-06-05 |
Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.1% |
| 1 month | -30.9% |
| 3 months | -59.6% |
| Year to date | -96.7% |
| 1 year | -97.4% |
| From 52-week high | -97.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| SLXN | Silexion Therapeutics Corp | $1.76 | -11.11% | $1.1M |
| SCNI | Scinai Immunotherapeutics Ltd. | $0.4041 | +1.02% | $1.1M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier